CRVS vs. ONCY, ENLV, ORGS, AYTU, TRDA, AVTE, HRTX, SIGA, FULC, and CDMO
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Oncolytics Biotech (ONCY), Enlivex Therapeutics (ENLV), Orgenesis (ORGS), Aytu BioPharma (AYTU), Entrada Therapeutics (TRDA), Aerovate Therapeutics (AVTE), Heron Therapeutics (HRTX), SIGA Technologies (SIGA), Fulcrum Therapeutics (FULC), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Oncolytics Biotech has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Oncolytics Biotech's return on equity of -59.96% beat Corvus Pharmaceuticals' return on equity.
Corvus Pharmaceuticals received 133 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 68.30% of users gave Oncolytics Biotech an outperform vote while only 62.31% of users gave Corvus Pharmaceuticals an outperform vote.
6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oncolytics Biotech currently has a consensus price target of $4.00, suggesting a potential upside of 280.95%. Corvus Pharmaceuticals has a consensus price target of $6.88, suggesting a potential upside of 238.67%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Oncolytics Biotech is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.24 beat Corvus Pharmaceuticals' score of 0.80 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.
Summary
Oncolytics Biotech beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
